Innate Pharma/$IPHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Ticker
$IPHA
Sector
Primary listing
Employees
174
Headquarters
Website
Innate Pharma Metrics
BasicAdvanced
$198M
-
-$0.64
0.91
-
Price and volume
Market cap
$198M
Beta
0.91
52-week high
$2.63
52-week low
$1.29
Average daily volume
17K
Financial strength
Current ratio
2.208
Quick ratio
2.081
Long term debt to equity
351.769
Total debt to equity
525.447
Interest coverage (TTM)
-102.40%
Profitability
EBITDA (TTM)
-57.886
Gross margin (TTM)
-243.65%
Net profit margin (TTM)
-364.44%
Operating margin (TTM)
-401.15%
Revenue per employee (TTM)
$81,410
Management effectiveness
Return on assets (TTM)
-25.92%
Return on equity (TTM)
-271.37%
Valuation
Price to revenue (TTM)
12.587
Price to book
33.14
Price to tangible book (TTM)
33.14
Price to free cash flow (TTM)
-3.855
Free cash flow yield (TTM)
-25.94%
Free cash flow per share (TTM)
-0.571
Growth
Revenue change (TTM)
-62.60%
Earnings per share change (TTM)
30.00%
3-year revenue growth (CAGR)
-39.47%
10-year revenue growth (CAGR)
4.51%
3-year earnings per share growth (CAGR)
24.36%
10-year earnings per share growth (CAGR)
4.56%
What the Analysts think about Innate Pharma
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Innate Pharma Financial Performance
Revenues and expenses
Innate Pharma Earnings Performance
Company profitability
Innate Pharma News
AllArticlesVideos
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
Business Wire2 weeks ago
Innate Pharma Reports First Half 2025 Business Update and Financial Results
Business Wire1 month ago
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $198M as of October 27, 2025.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of October 27, 2025.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of October 27, 2025.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.